Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

NOVIRUSES2BRAIN

Financiado

Cerrado

One size fits all unique drug to eradicate multiple viral species simultaneo...

One size fits all unique drug to eradicate multiple viral species simultaneously from the central nervous system of co infected individuals Viruses that infect the brain and other parts of the central nervous system are a worldwide threat of terrible dimensions. Viruses such as Zika, Dengue, Chikungunya, HIV or measles, for instance, and more recently the Severe acute... ver más

31/08/2025

iMM

4M€

Presupuesto del proyecto: 4M€

Líder del proyecto

INSTITUTO DE MEDICINA MOLECULAR JOAO LOBO ANT... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 3 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2018-12-17

FETOPEN-01-2018-2019-2020: FET-Open Challenging Current Thinki...

I+D

Cerrada hace 6 años

0% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

3 Participantes

iMM

2.11M€ | Lider

UPF

1.27M€ | Participante

Synovo

548.00K€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

RYC2018-025379-I Understanding molecular mechanisms underlying Zika virus ass... 309K€ Cerrado

ZIKVMosTransmit Molecular mechanisms underlying Zika virus transmission by A... 196K€ Cerrado

ZIKAVAX Fast track development of a Zika vaccine based on measles ve... 5M€ Cerrado

PID2019-106959RB-I00 VIRUS EMERGENTES: MODIFICACIONES DE ARN Y NUEVAS ESTRATEGIAS... 230K€ Cerrado

PID2019-106068GB-I00 DESCIFRANDO EL PAPEL BIOLOGICO DE LOS FACTORES CELULARES QUE... 169K€ Cerrado

PID2020-119710RB-I00 LA CASCADA EPIGENETICA DE INFECCIONES VIRALES NEUROTROPICAS 206K€ Cerrado

Duración del proyecto: 80 meses Fecha Inicio: 2018-12-17
Fecha Fin: 2025-08-31

Líder del proyecto

INSTITUTO DE MEDICINA MOLECULAR JOAO LOBO ANT... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 4M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Viruses that infect the brain and other parts of the central nervous system are a worldwide threat of terrible dimensions. Viruses such as Zika, Dengue, Chikungunya, HIV or measles, for instance, and more recently the Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are responsible for thousands of victims severely impaired at neurological level each year in the world. One of the most recent large scale threats in this domain was a Zika virus outbreak in South America. Zika virus, like Dengue virus or Chikungunya virus, is spread mainly by mosquitos of the genus Aedes. While Dengue and Chikungunya viruses, as many others, might causes diseases with severe neurological disorders, Zika virus is much more dreadful in this regard. When a pregnant woman is infected, the virus is able to translocate the blood-placental barrier and then the developing blood-brain barrier of the foetus, causing microcephaly and serious neurological disorders to newly born babies. Although co-infections with Aedes-borne viruses, such as the above mentioned Zika, Dengue and Chikungunya viruses, are likely because several viral species coexist in the same vector, the classical drug development strategies completely overlook this striking reality. Moreover, additional co-infections with HIV, SARS-CoV-2 and measles virus, using other routes of infection, are also possible. A drug able to target a very large spectrum of viral species is urgently needed. Importantly, this drug must be able to traverse the blood-brain barrier and reach the viruses accumulated in the brain. NOVIRUSES2BRAIN is a project that aims at finding and selecting drug leads that are both efficacious and able to translocate the blood-placental and blood-brain barriers so that Zika, Dengue, Chikungunya and other viruses, such as the recently discovered SARS-CoV-2 can be targeted across barriers, including during pregnancy. The project gathers the expertise of medicinal chemists, biochemists, drug development specialists and virologists to create drug leads able to clear all viral species from brain simultaneously.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores